Defunct Company
Total Trials
73
As Lead Sponsor
16
As Collaborator
57
Total Enrollment
6,000
NCT00085826
A Phase III Study of the Efficacy of Taxotere/Aptosyn Versus Taxotere/Placebo in Non-Small Cell Lung Cancer Patients
Phase: Phase 3
Role: Collaborator
Start: Apr 30, 2001
Completion: Dec 31, 2004
NCT00073489
A Pilot Study of OSI-461 in Patients With Chronic Lymphocytic Leukemia (CLL)
Phase: Phase 2
Start: May 31, 2001
Completion: Dec 31, 2003
NCT00033241
Erlotinib Combined With Gemcitabine in Treating Patients With Newly Diagnosed Locally Advanced or Metastatic Pancreatic Cancer or Other Solid Tumors
Phase: Phase 1
Role: Lead Sponsor
Start: Jul 23, 2001
Completion: Apr 22, 2004
NCT00036036
Study of CP-461 in Patients With Advanced Renal Cell Cancer
Start: Jul 31, 2001
Completion: Jul 31, 2003
NCT00036075
Study Using CP-461 to Treat Advanced Prostate Cancer
Start: Aug 31, 2001
Completion: Dec 31, 2005
NCT00072618
Phase II Study of Taxotere in Combination With Exisulind in Non-Small Cell Lung Cancer (NSCLC) Patients
Phase: Phase 1/2
Start: Oct 31, 2001
Completion: Aug 31, 2003
NCT00036647
OSI-774 (Tarceva) in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer
Start: Nov 1, 2001
Completion: Jan 30, 2004
NCT00040183
OSI-774 (Tarceva) Plus Gemcitabine in Patients With Locally Advanced, Unresectable or Metastatic Pancreatic Cancer.
Start: Nov 29, 2001
Completion: Jan 15, 2004
NCT00283803
Exisulind and Intermittent Androgen Suppression (ADT) in Biochemical Relapsed Prostate Cancer
Start: Mar 12, 2002
Completion: Oct 31, 2011
NCT00036257
Dose-Escalating and Safety Study of CP-461 in Patients With Chronic Lymphocytic Leukemia
Start: Mar 31, 2002
Completion: Apr 30, 2003
NCT00042055
CP-461 for the Treatment of Crohn's Disease
Start: Jul 31, 2002
Completion: Sep 30, 2003
NCT00046787
Efficacy and Safety Study of OSI-211 (Liposomal Lurtotecan) to Treat Recurrent Small Cell Lung Cancer
Start: Sep 30, 2002
Completion: Feb 28, 2003
NCT00046800
Study of OSI-211 vs. Topotecan in Patients With Relapsed Epithelial Ovarian Cancer
Completion: Mar 31, 2003
NCT00060710
CP-461 in the Treatment of Patients With Advanced Melanoma
Start: Jan 31, 2003
NCT00166426
Exisulind Versus Placebo After Surgical Removal of the Prostate
Start: Feb 28, 2003
Completion: May 31, 2008
NCT00123851
Tarceva, Capecitabine and Oxaliplatin for Metastatic Colorectal Cancer
Start: Mar 31, 2003
Completion: Aug 31, 2006
NCT00116896
Phase I Study of Cisplatin Plus OSI-7904L in Patients With Solid Tumors
Start: Jun 30, 2003
NCT00073502
Phase II Study of Single Agent OSI-7904L in Patients With Gastric or Gastroesophageal (GEJ) Cancer
Start: Oct 31, 2003
Completion: Oct 31, 2003
NCT00072631
Erlotinib (Tarceva (Trademark), OSI-774) in Treating Patients With Advanced Non-Small Cell Lung Cancer
Start: Nov 5, 2003
Completion: Mar 14, 2007
NCT00085839
Erlotinib vs. Standard Chemotherapy in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) and Eastern Cooperative Oncology Group (ECOG)Performance Status (PS) 2
Start: Feb 29, 2004
Completion: Mar 31, 2007
NCT00088270
A Study of OSI-7904L Versus 5-FU/LV as Treatment in Patients With Biliary Tract Cancer
Start: Aug 31, 2004
Completion: Aug 31, 2005
NCT00116909
A Study of OSI-7904L as Treatment in Patients With Head and Neck Cancer Who Have Failed First-Line Therapy
NCT00254410
FCM-R (Fludarabine, Cyclophosphamide, Mitoxantrone, Rituximab) in Previously Untreated Patients With Chronic Lymphocytic Leukemia (CLL) < 70 Years
Start: Mar 14, 2005
Completion: Sep 14, 2017
NCT00139620
A Pharmacokinetic Study of Erlotinib in Cancer Patients With Advanced Solid Tumors, With Adequate and Moderately Impaired Hepatic Function
Start: Aug 22, 2005
Completion: Jun 25, 2007
NCT00140556
Angiogenic and EGFR Blockade With Curative Chemoradiation for Advanced Head and Neck Cancer
Phase: Early Phase 1
Start: Aug 31, 2005
Completion: Apr 30, 2010
NCT00294736
A Two-Stage Phase 1 Dose Escalation Pharmacokinetic Study of Tarceva in Patients With Stage IIIB/IV Non-small Cell Lung Cancer Who Continue to Smoke After Failure of One or Two Prior Chemotherapy Regimens
Start: Nov 30, 2005
Completion: Sep 30, 2007
NCT01515137
Study of TARCEVA (Erlotinib) as Adjuvant Treatment for Locally Advanced Head and Neck Squamous Cell Carcinoma
Completion: Sep 30, 2014
NCT00294762
Erlotinib (Tarceva) as a Single Agent or Intercalated With Combination Chemotherapy in Patients With EGFR Positive NSCLC
Start: Jan 31, 2006
Completion: Mar 31, 2009
NCT00304278
Study of RADPLAT and Tarceva in Locally Advanced Head and Neck Squamous Cell Carcinoma (SCCA)
Start: Mar 31, 2006
Completion: Dec 31, 2015
NCT00513851
Phase 1 Study of OSI-930 in Cancer Patients
Start: Apr 30, 2006
Completion: Sep 30, 2009
NCT00950365
Pemetrexed Disodium With or Without Erlotinib Hydrochloride in Treating Patients With Stage IIIB-IV or Recurrent Non-Small Cell Lung Cancer
Completion: Nov 17, 2017
NCT00380029
Erlotinib Before and After Surgery in Treating Patients With Muscle-Invasive Bladder Cancer
Start: May 31, 2006
Completion: Jun 30, 2014
NCT00369512
A Trial of Erlotinib + Radiotherapy for Cutaneous Squamous Cell Carcinoma
Start: Aug 31, 2006
Completion: Sep 30, 2012
NCT00373425
A Study of Erlotinib (Tarceva) After Surgery With or Without Adjuvant Chemotherapy in Non-Small Cell Lung Carcinoma (NSCLC) Patients Who Have Epidermal Growth Factor Receptor (EGFR) Positive Tumors
Start: Sep 30, 2006
NCT00570258
Randomized, Double Blind Multicenter Phase II Study of Time to Progression on Fulvestrant in Combination With Erlotinib or Placebo in Hormone Receptor-Positive Metastatic Breast Cancer (MBC) Subjects Who Progressed on First Line Hormonal Therapy
Completion: Dec 31, 2017
NCT00385996
Pilot Study of Preoperative Tarceva (Erlotinib) for Stages I/II Non-Small Cell Lung Cancer
Start: Oct 31, 2006
Completion: Aug 31, 2011
NCT00392665
Bevacizumab/Tarceva and Tarceva/Sulindac in Squamous Cell Carcinoma of the Head and Neck
Completion: Dec 31, 2013
NCT00497224
Phase II Trial of Erlotinib in Advanced Pancreatic Cancer
Start: Nov 30, 2006
Completion: Jun 30, 2013
NCT00672243
Ph II Erlotinib + Sirolimus for Pts w Recurrent Malignant Glioma Multiforme
Start: Apr 30, 2007
Completion: Dec 31, 2009
NCT00553800
Study of Bevacizumab and Erlotinib in Patients With Advanced Non-small Cell Lung Cancer
Start: Jul 5, 2007
Completion: Jun 1, 2011
NCT01557959
Docetaxel, Cisplatin, Pegfilgrastim, and Erlotinib Hydrochloride in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer
Start: Jul 31, 2007
Completion: Feb 28, 2011
NCT00532441
Erlotinib in Combination With Docetaxel in Advanced Hepatocellular and Biliary Tract Carcinomas
Start: Sep 30, 2007
Completion: Aug 31, 2010
NCT00696696
Study of Gemcitabine and Erlotinib Plus Sorafenib (GES) in Metastatic Pancreatic Cancer
NCT00499655
Erlotinib Hydrochloride With or Without Celecoxib in Treating Patients With Stage IIIB-IV Non-Small Cell Lung Cancer
Start: Nov 30, 2007
Completion: Dec 31, 2016
NCT00603356
Phase I Study of OSI-930 and Erlotinib in Cancer Tumors
Completion: Jul 31, 2010
NCT00570232
UAB 0718 - Phase II Trial to Assess Target Oral Therapy as Adjuvant Chemoprevention in High-Risk Head and Neck Cancer
Start: Dec 31, 2007
Completion: Mar 31, 2015
NCT00591123
Study of Erlotinib and Chemotherapy for Unresectable or Metastatic Cancer of the Esophagus and Gastric Cardia
Completion: Sep 30, 2015
NCT00609804
Sorafenib and Erlotinib or Sorafenib Alone in Advanced Non-Small Cell Lung Cancer Progressing on Erlotinib
Start: Mar 31, 2008
Completion: Nov 30, 2014
NCT00640978
Erlotinib and RAD001 (Everolimus) in Patients With Previously Treated Advanced Pancreatic Cancer
Completion: Mar 31, 2010
NCT00642746
Erlotinib and Chemotherapy for 2nd Line Treatment (Tx) of Metastatic Colorectal Cancer (mCRC)
Completion: Dec 31, 2011
NCT00739063
Phase II Study of Erlotinib, an EGFR Inhibitor in Metastatic EGFR-positive 'Triple Receptor-negative' Breast Cancer
Start: Jul 31, 2008
Completion: Nov 30, 2010
NCT00826449
Dasatinib and Erlotinib in Non-Small Cell Lung Cancer (NSCLC)
Start: Feb 28, 2009
NCT00841035
7 Day's of Erlotinib Neo-adjuvant, Followed by Adjuvant Erlotinib-gemcitabine in Pancreatic Cancer Patients
Completion: Jul 31, 2011
NCT00871923
Tarceva With Whole Brain Radiation Therapy - Brain Mets From Non-Small Cell Lung Cancer
Start: Mar 26, 2009
Completion: Dec 4, 2019
NCT00733746
Gemcitabine and Erlotinib Before and After Surgery in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery
Start: Apr 30, 2009
Completion: Jun 15, 2019
NCT00942734
Trial of RAD001 and Erlotinib With Recurrent Head and Neck Squamous Cell Carcinoma
Start: Jul 31, 2009
NCT01003938
Topotecan With Erlotinib for Topotecan Pretreated Ovarian Cancer
Start: Aug 31, 2009
Completion: Dec 31, 2012
NCT01038856
Trial of Erlotinib in Patients With JAK-2 V617F Positive Polycythemia Vera
Start: Dec 31, 2009
Completion: Feb 28, 2014
NCT00940316
Dual Epidermal Growth Factor Receptor Inhibition With Erlotinib and Panitumumab With or Without Chemotherapy for Advanced Colorectal Cancer
Start: Jan 18, 2010
Completion: Jan 31, 2015
NCT01027598
Randomized, Double-Blind Trial of Erlotinib/Pazopanib or Erlotinib/Placebo in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer
Start: Jan 31, 2010
NCT01010945
Erlotinib, Gemcitabine and Nab-Paclitaxel in Advanced Pancreatic Cancer
Start: Feb 3, 2010
Completion: Jan 25, 2012
NCT01154335
Everolimus and OSI-906 for Patients With Refractory Metastatic Colorectal Cancer
Start: Jul 31, 2010
Completion: May 31, 2013
NCT01174043
Pilot Study of Erlotinib for the Treatment of Patients With de Novo Acute Myeloid Leukemia
Completion: Mar 31, 2012
NCT01032070
Erlotinib Versus Oral Etoposide in Patients With Recurrent or Refractory Pediatric Ependymoma
Start: Sep 27, 2010
Completion: Nov 26, 2012
NCT01299220
Study of Acitretin to Treat Skin Rash Caused by Erlotinib (a Chemotherapy Drug)
Phase: Phase 4
Start: Nov 30, 2010
Completion: Sep 30, 2011
NCT01257594
EGFR Inhibition Using Weekly Erlotinib for Recurrent Malignant Gliomas
Start: Jan 7, 2011
Completion: Dec 31, 2018
NCT01059305
Phase II Trial of Erlotinib, Prior to Surgery or Radiation in Patients With Squamous Cell Cancers (SCC) of the Skin
Start: Feb 28, 2011
Completion: Mar 31, 2016
NCT01334710
A Phase II Trial of OSI-906 and Sorafenib in Advanced Hepatocellular Cancer
Start: Mar 31, 2011
NCT01180959
Erlotinib Plus Bevacizumab in Hepatocellular Carcinoma (HCC) as Second-line Therapy
Start: Apr 14, 2011
Completion: May 19, 2021
NCT01247922
Single-agent Erlotinib in Patients Previously Treated With Oral Etoposide in Protocol OSI-774-205
Start: May 23, 2011
Completion: Sep 13, 2012
NCT01567384
A Phase I Study of OSI-906 in Combination With Pemetrexed in Advanced Solid Tumor Malignancies
Start: May 31, 2012
Completion: Oct 31, 2013
NCT01427205
Phase II Study of Cetuximab With or Without OSI-906 in Head and Neck Squamous Cell Carcinoma (HNSCC)
Start: Jun 30, 2013
Completion: Not specified